Fruquintinib (HMPL-013) is a potent and selective VEGFR1/2/3 inhibitor (IC50s = 33, 0.35, and 35 nM, respectively). It also inhibits RET, FGFR1, and c-Kit at higher concentrations. Fruquintinib suppresses VEGF-induced endothelial cell proliferation and tube formation and reduces tumor growth in multiple xenograft models. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.